A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms GRECO
- Sponsors AstraZeneca
- 04 Apr 2017 Planned End Date changed from 1 Nov 2017 to 24 Aug 2017.
- 04 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 24 Aug 2017.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.